Information  X 
Enter a valid email address

Accrol Group Hldgs (ACRL)

  Print      Mail a friend

Friday 23 November, 2018

Accrol Group Hldgs

Accrol Group to present at Mello London

RNS Number : 2528I
Accrol Group Holdings PLC
23 November 2018


23 November 2018


Accrol Group Holdings plc

("Accrol Group" or the "Company")



Accrol Group to present at Mello London


Accrol Group, the UK's leading independent tissue converter, is pleased to announce that the Company will be presenting at the Mello London investor conference, being held on on Monday, 26 November 2018 at the Clayton Hotel Chiswick, Chiswick High Road, London, W4 5RY. 


Gareth Jenkins, Chief Executive Officer, and Steve Townsley, Chief Financial Officer, will present to delegates between 4.00pm and 4.40pm on that day.


The presentation materials will be available on the Company's website following the event. No new material information will be disclosed.


For information on the conference and ticket availability, please visit the event website at







Accrol Group Holdings plc


Gareth Jenkins, Chief Executive Officer

Tel: +44 (0) 1254 278 844

Steve Townsley, Chief Financial Officer




Zeus Capital Limited (Nominated Adviser & Broker) 


Dan Bate / Andrew Jones            

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000



Belvedere Communications Limited


Cat Valentine ([email protected])

Tel: +44 (0) 7715 769 078

Llew Angus ([email protected])

Tel:  +44 (0)7407 023 147


Notes to Editors


Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK. 


Accrol operates from three sites:


·     A manufacturing, storage and distribution facility in Blackburn;

·     A facial tissue plant, also in Blackburn; and

·     A manufacturing, storage and distribution facility in Leyland.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t